A research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the original SARS illness.

In a virtual media briefing with reporters, Dr. Emmanuel Walter Jr., discussed his study findings, the overall vaccine trial process, potential side effects, and the need for herd immunity in American communities.

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $17.5 million over three years to the Duke Human Vaccine Institute to develop a vaccine that protects against multiple types of coronaviruses and viral variants.

A Q&A with Nobel Laureate Jennifer Doudna

Election to NAM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

About 38 million people worldwide are living with AIDS. Pharmaceutical treatments can keep the disease in check, but a vaccine remains elusive despite decades of concerted effort. However, a recent discovery at the Duke Human Vaccine Institute (DHVI) brings the goal of an effective vaccine within reach.

The National Institutes of Health (NIH) has awarded Susan D.

National breast cancer organization Susan G. Komen announced, on Sept.

Duke University is one of three sites that have been awarded a total of $4.4 million National Institutes of Health/National Cancer Institute Cancer Intervention and Surveillance Modeling Network (C

On October 8, the FDA approved a regenerative medicine based on Louise Markert, M.D., Ph.D.'s,  pioneering work as the only therapy